$GYHT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in HALOZYME THERAPEUTICS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in HALOZYME THERAPEUTICS, INC.. Get notifications about new insider transactions in HALOZYME THERAPEUTICS, INC. for free.
Page: < prev 1 ... 2 3 4 5 6 7 8 9 ... 15 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 11 2011 | GYHT | HALOZYME THERAPEUT ... | Shepard H. Michael | VP, Chief Scientifi ... | Option Exercise | A | 0.00 | 18,000 | 0 | 18,000 | |
May 11 2011 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | VP, Product Develop ... | Option Exercise | A | 0.00 | 19,000 | 0 | 19,000 | |
May 11 2011 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | VP, Chief Scientifi ... | Option Exercise | A | 0.00 | 26,000 | 0 | 26,000 | |
May 11 2011 | GYHT | HALOZYME THERAPEUT ... | GUSTAFSON KURT A | Vice President and ... | Option Exercise | A | 0.00 | 24,000 | 0 | 24,000 | |
May 11 2011 | GYHT | HALOZYME THERAPEUT ... | Fallon William J | VP, Manufacturing & ... | Option Exercise | A | 0.00 | 19,000 | 0 | 19,000 | |
May 09 2011 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Grant | A | 0.00 | 20,000 | 0 | 3,430,000 | 3.4 M to 3.4 M (+0.59 %) |
May 06 2011 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | President and CEO | Option Exercise | A | 6.21 | 2,000 | 12,420 | 2,000 | |
May 06 2011 | GYHT | HALOZYME THERAPEUT ... | Engler Robert | Director | Grant | A | 0.00 | 20,000 | 20 | 125,000 | 105 K to 125 K (+19.05 %) |
May 06 2011 | GYHT | HALOZYME THERAPEUT ... | MATSUI CONNIE | Director | Grant | A | 0.00 | 20,000 | 20 | 105,000 | 85 K to 105 K (+23.53 %) |
May 06 2011 | GYHT | HALOZYME THERAPEUT ... | FALBERG KATHRYN E | Director | Grant | A | 0.00 | 20,000 | 20 | 90,000 | 70 K to 90 K (+28.57 %) |
May 06 2011 | GYHT | HALOZYME THERAPEUT ... | Kelley Kenneth J | Director | Grant | A | 0.00 | 20,000 | 20 | 90,000 | 70 K to 90 K (+28.57 %) |
May 06 2011 | GYHT | HALOZYME THERAPEUT ... | PATTON JOHN STUART | Director | Grant | A | 0.00 | 20,000 | 20 | 90,000 | 70 K to 90 K (+28.57 %) |
Feb 04 2011 | GYHT | HALOZYME THERAPEUT ... | Shepard H. Michael | VP, Chief Scientifi ... | Option Exercise | A | 7.14 | 40,000 | 285,600 | 40,000 | |
Feb 04 2011 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | VP, Product Develop ... | Option Exercise | A | 7.14 | 40,000 | 285,600 | 40,000 | |
Feb 04 2011 | GYHT | HALOZYME THERAPEUT ... | Fallon William J | VP, Manufacturing & ... | Option Exercise | A | 7.14 | 40,000 | 285,600 | 40,000 | |
Feb 04 2011 | GYHT | HALOZYME THERAPEUT ... | GUSTAFSON KURT A | Vice President and ... | Option Exercise | A | 7.14 | 40,000 | 285,600 | 40,000 | |
May 10 2010 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Grant | A | 0.00 | 20,000 | 0 | 3,410,000 | 3.4 M to 3.4 M (+0.59 %) |
May 06 2010 | GYHT | HALOZYME THERAPEUT ... | Kelley Kenneth J | Director | Grant | A | 0.00 | 20,000 | 20 | 70,000 | 50 K to 70 K (+40.00 %) |
May 06 2010 | GYHT | HALOZYME THERAPEUT ... | MATSUI CONNIE | Director | Grant | A | 0.00 | 20,000 | 20 | 85,000 | 65 K to 85 K (+30.77 %) |
May 06 2010 | GYHT | HALOZYME THERAPEUT ... | PATTON JOHN STUART | Director | Grant | A | 0.00 | 20,000 | 20 | 70,000 | 50 K to 70 K (+40.00 %) |
May 06 2010 | GYHT | HALOZYME THERAPEUT ... | FALBERG KATHRYN E | Director | Grant | A | 0.00 | 20,000 | 20 | 70,000 | 50 K to 70 K (+40.00 %) |
May 06 2010 | GYHT | HALOZYME THERAPEUT ... | Engler Robert | Director | Grant | A | 0.00 | 20,000 | 20 | 105,000 | 85 K to 105 K (+23.53 %) |
Feb 08 2010 | GYHT | HALOZYME THERAPEUT ... | LITTLE ROBERT J | VP, Chief Commercia ... | Option Exercise | A | 5.55 | 7,576 | 42,047 | 7,576 | |
Feb 08 2010 | GYHT | HALOZYME THERAPEUT ... | LITTLE ROBERT J | VP, Chief Commercia ... | Option Exercise | A | 5.55 | 20,424 | 113,353 | 20,424 | |
Feb 08 2010 | GYHT | HALOZYME THERAPEUT ... | Fallon William J | VP, Manufacturing & ... | Option Exercise | A | 5.55 | 22,517 | 124,969 | 22,517 | |
Feb 08 2010 | GYHT | HALOZYME THERAPEUT ... | Fallon William J | VP, Manufacturing & ... | Option Exercise | A | 5.55 | 17,483 | 97,031 | 17,483 | |
Feb 08 2010 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | VP, Chief Scientifi ... | Option Exercise | A | 5.55 | 62,313 | 345,837 | 62,313 | |
Feb 08 2010 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | VP, Chief Scientifi ... | Option Exercise | A | 5.55 | 17,687 | 98,163 | 17,687 | |
Feb 08 2010 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | Chief Executive Off ... | Option Exercise | A | 5.55 | 102,478 | 568,753 | 102,478 | |
Feb 08 2010 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | Chief Executive Off ... | Option Exercise | A | 5.55 | 17,522 | 97,247 | 17,522 | |
Feb 08 2010 | GYHT | HALOZYME THERAPEUT ... | GUSTAFSON KURT A | Vice President and ... | Option Exercise | A | 5.55 | 25,312 | 140,482 | 25,312 | |
Feb 08 2010 | GYHT | HALOZYME THERAPEUT ... | GUSTAFSON KURT A | Vice President and ... | Option Exercise | A | 5.55 | 1,288 | 7,148 | 1,288 | |
Jan 14 2010 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | Chief Executive Off ... | Option Exercise | M | 0.39 | 30,000 | 11,700 | 529,949 | |
Jan 14 2010 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | Chief Executive Off ... | Buy | M | 0.39 | 30,000 | 11,700 | 710,000 | 680 K to 710 K (+4.41 %) |
Aug 07 2009 | GYHT | HALOZYME THERAPEUT ... | Leff Jonathan A | VP, Chief Medical O ... | Option Exercise | A | 7.48 | 200,000 | 1,496,000 | 200,000 | |
May 08 2009 | GYHT | HALOZYME THERAPEUT ... | MATSUI CONNIE | Director | Grant | A | 0.00 | 20,000 | 20 | 65,000 | 45 K to 65 K (+44.44 %) |
May 08 2009 | GYHT | HALOZYME THERAPEUT ... | Kelley Kenneth J | Director | Grant | A | 0.00 | 20,000 | 20 | 50,000 | 30 K to 50 K (+66.67 %) |
May 08 2009 | GYHT | HALOZYME THERAPEUT ... | FALBERG KATHRYN E | Director | Grant | A | 0.00 | 20,000 | 20 | 50,000 | 30 K to 50 K (+66.67 %) |
May 08 2009 | GYHT | HALOZYME THERAPEUT ... | Engler Robert | Director | Grant | A | 0.00 | 20,000 | 20 | 85,000 | 65 K to 85 K (+30.77 %) |
May 08 2009 | GYHT | HALOZYME THERAPEUT ... | PATTON JOHN STUART | Director | Grant | A | 0.00 | 20,000 | 20 | 50,000 | 30 K to 50 K (+66.67 %) |
May 08 2009 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Grant | A | 0.00 | 20,000 | 0 | 3,390,000 | 3.4 M to 3.4 M (+0.59 %) |
Feb 09 2009 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | Secretary, CFO | Option Exercise | A | 6.10 | 30,000 | 183,000 | 523,438 | |
Feb 09 2009 | GYHT | HALOZYME THERAPEUT ... | LITTLE ROBERT J | VP-Chief Commercial ... | Option Exercise | A | 6.10 | 20,000 | 122,000 | 259,661 | |
Feb 09 2009 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | President, CEO | Option Exercise | A | 6.10 | 120,000 | 732,000 | 2,149,003 | |
Feb 09 2009 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | VP and Chief Scient ... | Option Exercise | A | 6.10 | 80,000 | 488,000 | 257,480 | |
Feb 09 2009 | GYHT | HALOZYME THERAPEUT ... | Fallon William J | VP-Manufacturing an ... | Option Exercise | A | 6.10 | 40,000 | 244,000 | 228,800 | |
Dec 18 2008 | GYHT | HALOZYME THERAPEUT ... | Engler Robert | Director | Buy | P | 4.38 | 10,000 | 43,800 | 65,000 | 55 K to 65 K (+18.18 %) |
Jul 14 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Option Exercise | X | 1.75 | 136,300 | 238,525 | 0 | |
Jul 14 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | X | 1.75 | 136,300 | 238,525 | 1,436,186 | 1.3 M to 1.4 M (+10.49 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.51 | 1,500 | 8,265 | 1,299,886 | 1.3 M to 1.3 M (+0.12 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.52 | 500 | 2,760 | 1,298,386 | 1.3 M to 1.3 M (+0.04 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.53 | 3,300 | 18,249 | 1,297,886 | 1.3 M to 1.3 M (+0.25 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.55 | 22,344 | 124,009 | 1,294,586 | 1.3 M to 1.3 M (+1.76 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.57 | 819 | 4,562 | 1,272,242 | 1.3 M to 1.3 M (+0.06 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Option Exercise | P | 1.75 | 136,300 | 238,525 | 136,300 | |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.58 | 200 | 1,116 | 1,271,423 | 1.3 M to 1.3 M (+0.02 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.59 | 300 | 1,677 | 1,271,223 | 1.3 M to 1.3 M (+0.02 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.60 | 4,271 | 23,918 | 1,270,923 | 1.3 M to 1.3 M (+0.34 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.61 | 4,200 | 23,562 | 1,266,652 | 1.3 M to 1.3 M (+0.33 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.62 | 10,400 | 58,448 | 1,262,452 | 1.3 M to 1.3 M (+0.83 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.63 | 9,100 | 51,233 | 1,252,052 | 1.2 M to 1.3 M (+0.73 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.64 | 136,761 | 771,332 | 1,242,952 | 1.1 M to 1.2 M (+12.36 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.65 | 13,092 | 73,970 | 1,106,191 | 1.1 M to 1.1 M (+1.20 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.66 | 9,800 | 55,468 | 1,093,099 | 1.1 M to 1.1 M (+0.90 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.67 | 10,808 | 61,281 | 1,083,299 | 1.1 M to 1.1 M (+1.01 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.68 | 6,700 | 38,056 | 1,072,491 | 1.1 M to 1.1 M (+0.63 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.69 | 6,400 | 36,416 | 1,065,791 | 1.1 M to 1.1 M (+0.60 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.70 | 24,100 | 137,370 | 1,059,391 | 1 M to 1.1 M (+2.33 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.71 | 23,504 | 134,208 | 1,035,291 | 1 M to 1 M (+2.32 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.72 | 1,496 | 8,557 | 1,011,787 | 1 M to 1 M (+0.15 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.78 | 5,000 | 28,900 | 1,010,291 | 1 M to 1 M (+0.50 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.79 | 1,200 | 6,948 | 1,005,291 | 1 M to 1 M (+0.12 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.80 | 6,220 | 36,076 | 1,004,091 | 997.9 K to 1 M (+0.62 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.81 | 1,300 | 7,553 | 997,871 | 996.6 K to 997.9 K (+0.13 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.82 | 1,200 | 6,984 | 996,571 | 995.4 K to 996.6 K (+0.12 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.83 | 7,000 | 40,810 | 995,371 | 988.4 K to 995.4 K (+0.71 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.84 | 3,080 | 17,987 | 988,371 | 985.3 K to 988.4 K (+0.31 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.93 | 427,100 | 2,532,703 | 985,291 | 558.2 K to 985.3 K (+76.52 %) |
Jun 23 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.85 | 175,500 | 1,026,675 | 558,191 | 382.7 K to 558.2 K (+45.86 %) |
Jun 23 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 6.02 | 59,900 | 360,598 | 382,691 | 322.8 K to 382.7 K (+18.56 %) |
Jun 18 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.76 | 36,827 | 212,124 | 322,791 | 286 K to 322.8 K (+12.88 %) |
Jun 18 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.98 | 42,000 | 251,160 | 285,964 | 244 K to 286 K (+17.22 %) |
Jun 18 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.73 | 25,800 | 147,834 | 243,964 | 218.2 K to 244 K (+11.83 %) |
Jun 13 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.53 | 45,725 | 252,859 | 218,164 | 172.4 K to 218.2 K (+26.52 %) |
Jun 13 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.42 | 57,000 | 308,940 | 172,439 | 115.4 K to 172.4 K (+49.38 %) |
Jun 13 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.27 | 115,439 | 608,364 | 115,439 | 0 to 115.4 K |
May 12 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Option Exercise | A | 4.94 | 10,000 | 49,400 | 10,000 | |
May 12 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Grant | A | 0.00 | 15,000 | 0 | 370,000 | 355 K to 370 K (+4.23 %) |
May 09 2008 | GYHT | HALOZYME THERAPEUT ... | Thornton Steven T | Director | Option Exercise | A | 4.94 | 10,000 | 49,400 | 20,000 | |
May 09 2008 | GYHT | HALOZYME THERAPEUT ... | Thornton Steven T | Director | Grant | A | 4.94 | 15,000 | 74,100 | 30,000 | 15 K to 30 K (+100.00 %) |
May 09 2008 | GYHT | HALOZYME THERAPEUT ... | PATTON JOHN STUART | Director | Option Exercise | A | 4.94 | 10,000 | 49,400 | 30,000 | |
May 09 2008 | GYHT | HALOZYME THERAPEUT ... | PATTON JOHN STUART | Director | Grant | A | 4.94 | 15,000 | 74,100 | 30,000 | 15 K to 30 K (+100.00 %) |
May 09 2008 | GYHT | HALOZYME THERAPEUT ... | MATSUI CONNIE | Director | Option Exercise | A | 4.94 | 10,000 | 49,400 | 30,000 | |
May 09 2008 | GYHT | HALOZYME THERAPEUT ... | MATSUI CONNIE | Director | Grant | A | 4.94 | 15,000 | 74,100 | 45,000 | 30 K to 45 K (+50.00 %) |
May 09 2008 | GYHT | HALOZYME THERAPEUT ... | Kelley Kenneth J | Director | Option Exercise | A | 4.94 | 10,000 | 49,400 | 20,000 | |
May 09 2008 | GYHT | HALOZYME THERAPEUT ... | Kelley Kenneth J | Director | Grant | A | 4.94 | 15,000 | 74,100 | 30,000 | 15 K to 30 K (+100.00 %) |
May 09 2008 | GYHT | HALOZYME THERAPEUT ... | FALBERG KATHRYN E | Director | Option Exercise | A | 4.94 | 10,000 | 49,400 | 20,000 | |
May 09 2008 | GYHT | HALOZYME THERAPEUT ... | FALBERG KATHRYN E | Director | Grant | A | 4.94 | 15,000 | 74,100 | 30,000 | 15 K to 30 K (+100.00 %) |
May 09 2008 | GYHT | HALOZYME THERAPEUT ... | Engler Robert | Director | Option Exercise | A | 4.94 | 10,000 | 49,400 | 255,000 | |
May 09 2008 | GYHT | HALOZYME THERAPEUT ... | Engler Robert | Director | Grant | A | 4.94 | 15,000 | 74,100 | 55,000 | 40 K to 55 K (+37.50 %) |
Mar 24 2008 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | VP and Chief Scient ... | Sell | S | 6.06 | 230,000 | 1,393,800 | 3,530,866 | 3.8 M to 3.5 M (-6.12 %) |
Mar 24 2008 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | President, CEO | Sell | S | 6.06 | 250,000 | 1,515,000 | 680,000 | 930 K to 680 K (-26.88 %) |
Mar 24 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 6.06 | 580,000 | 3,514,800 | 6,328,853 | 5.7 M to 6.3 M (+10.09 %) |
Mar 24 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 6.12 | 684,657 | 4,190,101 | 5,748,853 | 5.1 M to 5.7 M (+13.52 %) |
Mar 21 2008 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | President, CEO | Option Exercise | M | 0.39 | 230,000 | 89,700 | 2,029,003 | |
Mar 21 2008 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | President, CEO | Buy | M | 0.39 | 230,000 | 89,700 | 930,000 | 700 K to 930 K (+32.86 %) |
Mar 21 2008 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | VP and Chief Scient ... | Option Exercise | M | 0.43 | 639,902 | 275,158 | 177,480 | |
Mar 21 2008 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | VP and Chief Scient ... | Payment of Exercise | F | 6.06 | 28,642 | 173,571 | 3,760,866 | 3.8 M to 3.8 M (-0.76 %) |
Mar 21 2008 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | VP and Chief Scient ... | Buy | M | 0.43 | 639,902 | 275,158 | 3,789,508 | 3.1 M to 3.8 M (+20.32 %) |
Mar 20 2008 | GYHT | HALOZYME THERAPEUT ... | LITTLE ROBERT J | VP, Chief Commercia ... | Buy | P | 5.99 | 3,000 | 17,970 | 13,000 | 10 K to 13 K (+30.00 %) |
Mar 20 2008 | GYHT | HALOZYME THERAPEUT ... | LITTLE ROBERT J | VP, Chief Commercia ... | Buy | P | 5.98 | 200 | 1,196 | 10,000 | 9.8 K to 10 K (+2.04 %) |
Mar 20 2008 | GYHT | HALOZYME THERAPEUT ... | LITTLE ROBERT J | VP, Chief Commercia ... | Buy | P | 5.97 | 2,000 | 11,940 | 9,800 | 7.8 K to 9.8 K (+25.64 %) |
Mar 20 2008 | GYHT | HALOZYME THERAPEUT ... | LITTLE ROBERT J | VP, Chief Commercia ... | Buy | P | 5.96 | 3,800 | 22,648 | 7,800 | 4 K to 7.8 K (+95.00 %) |
Mar 20 2008 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | Secretary, CFO | Buy | P | 4.60 | 4,400 | 20,240 | 411,410 | 407 K to 411.4 K (+1.08 %) |
Mar 20 2008 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | Secretary, CFO | Buy | P | 4.55 | 2,500 | 11,375 | 407,010 | 404.5 K to 407 K (+0.62 %) |
Mar 20 2008 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | Secretary, CFO | Buy | P | 4.50 | 3,100 | 13,950 | 404,510 | 401.4 K to 404.5 K (+0.77 %) |
Mar 20 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.80 | 886,650 | 5,142,570 | 5,064,196 | 4.2 M to 5.1 M (+21.22 %) |
Mar 20 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 4.57 | 207,546 | 948,485 | 4,177,546 | 4 M to 4.2 M (+5.23 %) |
Mar 20 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.80 | 886,650 | 5,142,570 | 5,064,196 | 4.2 M to 5.1 M (+21.22 %) |
Mar 20 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 4.57 | 207,546 | 948,485 | 4,177,546 | 4 M to 4.2 M (+5.23 %) |
Feb 08 2008 | GYHT | HALOZYME THERAPEUT ... | Yocum Richard C | VP-Clinical Develop ... | Option Exercise | A | 5.60 | 28,800 | 161,280 | 150,943 | |
Feb 08 2008 | GYHT | HALOZYME THERAPEUT ... | RAMSAY DAVID A | Secretary, CFO | Option Exercise | A | 5.60 | 28,800 | 161,280 | 493,438 | |
Feb 08 2008 | GYHT | HALOZYME THERAPEUT ... | LITTLE ROBERT J | VP-Chief Commercial ... | Option Exercise | A | 5.60 | 28,800 | 161,280 | 239,661 | |
Feb 08 2008 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | President, CEO | Option Exercise | A | 5.60 | 50,000 | 280,000 | 2,232,313 | |
Feb 08 2008 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | VP and Chief Scient ... | Option Exercise | A | 5.60 | 50,000 | 280,000 | 747,141 | |
Feb 08 2008 | GYHT | HALOZYME THERAPEUT ... | Fallon William J | VP-Manufacturing an ... | Option Exercise | A | 5.60 | 28,800 | 161,280 | 188,800 | |
Dec 21 2007 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | VP and Chief Scient ... | Option Exercise | M | 0.43 | 9,736 | 4,186 | 697,141 | |
Dec 21 2007 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | VP and Chief Scient ... | Sell | S | 7.00 | 9,137 | 63,959 | 3,149,606 | 3.2 M to 3.1 M (-0.29 %) |
Dec 21 2007 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | VP and Chief Scient ... | Payment of Exercise | F | 6.98 | 599 | 4,181 | 3,158,743 | 3.2 M to 3.2 M (-0.02 %) |
Dec 21 2007 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | VP and Chief Scient ... | Buy | M | 0.43 | 9,736 | 4,186 | 3,159,342 | 3.1 M to 3.2 M (+0.31 %) |
Dec 12 2007 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | VP and Chief Scient ... | Option Exercise | M | 0.43 | 42,760 | 18,387 | 706,877 | |
Dec 12 2007 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | VP and Chief Scient ... | Payment of Exercise | F | 6.66 | 2,760 | 18,382 | 3,149,606 | 3.2 M to 3.1 M (-0.09 %) |
Dec 12 2007 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | VP and Chief Scient ... | Buy | M | 0.43 | 42,760 | 18,387 | 3,152,366 | 3.1 M to 3.2 M (+1.38 %) |
Dec 04 2007 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | President, CEO | Option Exercise | M | 0.39 | 20,000 | 7,800 | 2,182,313 | |
Dec 04 2007 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | President, CEO | Sell | S | 8.06 | 100 | 806 | 700,000 | 700.1 K to 700 K (-0.01 %) |
Dec 04 2007 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | President, CEO | Sell | S | 8.16 | 800 | 6,528 | 700,100 | 700.9 K to 700.1 K (-0.11 %) |
Dec 04 2007 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | President, CEO | Sell | S | 8.17 | 602 | 4,918 | 700,900 | 701.5 K to 700.9 K (-0.09 %) |
Dec 04 2007 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | President, CEO | Sell | S | 8.18 | 1,200 | 9,816 | 701,502 | 702.7 K to 701.5 K (-0.17 %) |
Dec 04 2007 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | President, CEO | Sell | S | 8.19 | 298 | 2,441 | 702,702 | 703 K to 702.7 K (-0.04 %) |
Dec 04 2007 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | President, CEO | Sell | S | 8.20 | 1,440 | 11,808 | 703,000 | 704.4 K to 703 K (-0.20 %) |
Dec 04 2007 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | President, CEO | Sell | S | 8.21 | 3,360 | 27,586 | 704,440 | 707.8 K to 704.4 K (-0.47 %) |
Dec 04 2007 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | President, CEO | Sell | S | 8.23 | 1,600 | 13,168 | 707,800 | 709.4 K to 707.8 K (-0.23 %) |
Dec 04 2007 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | President, CEO | Sell | S | 8.25 | 5,100 | 42,075 | 709,400 | 714.5 K to 709.4 K (-0.71 %) |
Dec 04 2007 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | President, CEO | Sell | S | 8.26 | 300 | 2,478 | 714,500 | 714.8 K to 714.5 K (-0.04 %) |
Dec 04 2007 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | President, CEO | Sell | S | 8.27 | 400 | 3,308 | 714,800 | 715.2 K to 714.8 K (-0.06 %) |
Dec 04 2007 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | President, CEO | Sell | S | 8.29 | 100 | 829 | 715,200 | 715.3 K to 715.2 K (-0.01 %) |
Dec 04 2007 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | President, CEO | Sell | S | 8.30 | 2,132 | 17,696 | 715,300 | 717.4 K to 715.3 K (-0.30 %) |
Dec 04 2007 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | President, CEO | Sell | S | 8.31 | 2,568 | 21,340 | 717,432 | 720 K to 717.4 K (-0.36 %) |
Dec 04 2007 | GYHT | HALOZYME THERAPEUT ... | Lim Jonathan E | President, CEO | Buy | M | 0.39 | 20,000 | 7,800 | 720,000 | 700 K to 720 K (+2.86 %) |
Nov 21 2007 | GYHT | HALOZYME THERAPEUT ... | Frost Gregory Ian | VP and Chief Scient ... | Option Exercise | M | 0.43 | 10,603 | 4,559 | 749,637 |